Responses
Regular and Young Investigator Award Abstracts
Clinical Trials Completed
558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study
Compose a Response to This Article
Other responses
No responses have been published for this article.